SU1197566A3 - Способ получени производных имидазолина - Google Patents
Способ получени производных имидазолина Download PDFInfo
- Publication number
- SU1197566A3 SU1197566A3 SU823385605A SU3385605A SU1197566A3 SU 1197566 A3 SU1197566 A3 SU 1197566A3 SU 823385605 A SU823385605 A SU 823385605A SU 3385605 A SU3385605 A SU 3385605A SU 1197566 A3 SU1197566 A3 SU 1197566A3
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- compound
- methyl
- imidazoline
- formula
- mixture
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 5
- 150000002462 imidazolines Chemical class 0.000 title abstract description 3
- 229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 6
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 abstract description 8
- 231100000252 nontoxic Toxicity 0.000 abstract description 7
- 230000003000 nontoxic effect Effects 0.000 abstract description 7
- 230000008485 antagonism Effects 0.000 abstract description 6
- 230000003518 presynaptic effect Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 5
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- -1 Hydrochloride (2-methyl-1,4-benzodioxanyl) 2-imidazoline Chemical compound 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 230000001242 postsynaptic effect Effects 0.000 description 10
- 239000005557 antagonist Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- PNXYEGILYPEDQA-UHFFFAOYSA-N 3-methyl-2h-1,4-benzodioxine-3-carboxylic acid Chemical compound C1=CC=C2OC(C)(C(O)=O)COC2=C1 PNXYEGILYPEDQA-UHFFFAOYSA-N 0.000 description 2
- 229940124225 Adrenoreceptor agonist Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- COVOGSVTXJYOLR-UHFFFAOYSA-N CC(=C)C1(COC2=CC=CC=C2O1)N3CCN=C3 Chemical compound CC(=C)C1(COC2=CC=CC=C2O1)N3CCN=C3 COVOGSVTXJYOLR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 150000002440 hydroxy compounds Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 2
- 229960001289 prazosin Drugs 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- AUTFPLSMEDVRPW-UHFFFAOYSA-N (3-methyl-2h-1,4-benzodioxin-3-yl)methanol Chemical compound C1=CC=C2OC(C)(CO)COC2=C1 AUTFPLSMEDVRPW-UHFFFAOYSA-N 0.000 description 1
- LFRHMTZYADABJZ-UHFFFAOYSA-N 1-(1,3-benzodioxol-5-yl)butan-2-amine;hydron;chloride Chemical compound Cl.CCC(N)CC1=CC=C2OCOC2=C1 LFRHMTZYADABJZ-UHFFFAOYSA-N 0.000 description 1
- ORJZEZMNVRXNGA-UHFFFAOYSA-N 1-chloro-2-(chloromethyl)pentan-2-ol Chemical compound CCCC(O)(CCl)CCl ORJZEZMNVRXNGA-UHFFFAOYSA-N 0.000 description 1
- DNLJHDDOVWQQEW-UHFFFAOYSA-N 2,3-dihydro-1,4-benzodioxine-3-carbonitrile Chemical compound C1=CC=C2OC(C#N)COC2=C1 DNLJHDDOVWQQEW-UHFFFAOYSA-N 0.000 description 1
- QWQPNHJXUKUZSZ-UHFFFAOYSA-N 3-(2-hydroxypropan-2-yl)-2h-1,4-benzodioxine-3-carbonitrile Chemical compound C1=CC=C2OC(C(C)(O)C)(C#N)COC2=C1 QWQPNHJXUKUZSZ-UHFFFAOYSA-N 0.000 description 1
- BVURMDFNGXCOPZ-UHFFFAOYSA-N 3-ethyl-2,3-dihydro-1,4-benzodioxine;methanol Chemical compound OC.C1=CC=C2OC(CC)COC2=C1 BVURMDFNGXCOPZ-UHFFFAOYSA-N 0.000 description 1
- HWYICNJWLYVBPJ-UHFFFAOYSA-N 3-methyl-2,4-dihydro-1,5-benzodioxepin-3-ol Chemical compound O1CC(C)(O)COC2=CC=CC=C21 HWYICNJWLYVBPJ-UHFFFAOYSA-N 0.000 description 1
- LVRGXTVGBMLTFC-UHFFFAOYSA-N 3-methyl-2h-1,4-benzodioxine-3-carboxamide Chemical compound C1=CC=C2OC(C)(C(N)=O)COC2=C1 LVRGXTVGBMLTFC-UHFFFAOYSA-N 0.000 description 1
- NUTOOFHNNGPCHO-UHFFFAOYSA-N 3-prop-1-en-2-yl-2h-1,4-benzodioxine-3-carbonitrile Chemical compound C1=CC=C2OC(C(=C)C)(C#N)COC2=C1 NUTOOFHNNGPCHO-UHFFFAOYSA-N 0.000 description 1
- DKTUYCBUKIUYCA-UHFFFAOYSA-N 3-propan-2-yl-2,3-dihydro-1,4-benzodioxine Chemical compound C1=CC=C2OC(C(C)C)COC2=C1 DKTUYCBUKIUYCA-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- SHQSVMDWKBRBGB-UHFFFAOYSA-N cyclobutanone Chemical compound O=C1CCC1 SHQSVMDWKBRBGB-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- UGVPKMAWLOMPRS-UHFFFAOYSA-M magnesium;propane;bromide Chemical compound [Mg+2].[Br-].CC[CH2-] UGVPKMAWLOMPRS-UHFFFAOYSA-M 0.000 description 1
- 229960003955 mianserin Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 description 1
- 229960001999 phentolamine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8102906 | 1981-01-30 | ||
| GB8123277 | 1981-07-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1197566A3 true SU1197566A3 (ru) | 1985-12-07 |
Family
ID=26278285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU823385605A SU1197566A3 (ru) | 1981-01-30 | 1982-01-28 | Способ получени производных имидазолина |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US4397860A (enExample) |
| EP (1) | EP0058006B1 (enExample) |
| AR (1) | AR229957A1 (enExample) |
| AU (1) | AU545344B2 (enExample) |
| CA (1) | CA1176638A (enExample) |
| CS (1) | CS245766B2 (enExample) |
| DE (1) | DE3262919D1 (enExample) |
| DK (1) | DK40482A (enExample) |
| ES (1) | ES8302694A1 (enExample) |
| FI (1) | FI67544C (enExample) |
| GB (1) | GB2092139B (enExample) |
| GR (1) | GR75168B (enExample) |
| HU (1) | HU190983B (enExample) |
| IE (1) | IE52310B1 (enExample) |
| IL (1) | IL64880A (enExample) |
| NO (1) | NO156865C (enExample) |
| NZ (1) | NZ199469A (enExample) |
| PH (1) | PH17747A (enExample) |
| PL (1) | PL137716B1 (enExample) |
| PT (1) | PT74354B (enExample) |
| SU (1) | SU1197566A3 (enExample) |
| ZW (1) | ZW1882A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ203680A (en) * | 1982-04-17 | 1985-08-16 | Reckitt & Colmann Prod Ltd | Imidazolines and pharmaceutical compositions |
| US4634714A (en) * | 1983-12-01 | 1987-01-06 | American Home Products Corporation | Inhibition of prolactin release by a benzodioxinylimidazoline derivative |
| FR2698789B1 (fr) * | 1992-12-07 | 1995-03-03 | Pf Medicament | Utilisation de l'idazoxan et ses dérivés pour la préparation d'un médicament destiné au traitement de la maladie de Parkinson et de son évolution. |
| FR2700113B1 (fr) * | 1993-01-07 | 1995-03-24 | Pf Medicament | Utilisation de l'Idazoxan et ses dérivés pour la fabrication de médicaments destinés au traitement des maladies neurodégénératives et en particulier l'évolution de la maladie d'Alzheimer. |
| US6162455A (en) * | 1997-01-22 | 2000-12-19 | American Cyanamid Company | Method for increasing lean meat, improving the lean meat to fat ratio and improving amino acid utilization in warm-blooded animals |
| FR2766824B1 (fr) * | 1997-07-30 | 1999-09-10 | Adir | Nouveaux composes heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US6650943B1 (en) | 2000-04-07 | 2003-11-18 | Advanced Bionics Corporation | Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction |
| US6885895B1 (en) * | 2001-04-26 | 2005-04-26 | Advanced Bionics Corporation | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
| US20050240229A1 (en) * | 2001-04-26 | 2005-10-27 | Whitehurst Tood K | Methods and systems for stimulation as a therapy for erectile dysfunction |
| RU2223450C1 (ru) * | 2002-06-25 | 2004-02-10 | Долотовский Владимир Васильевич | Водонагреватель емкостной газовый |
| CN103030646B (zh) * | 2011-09-29 | 2016-08-24 | 上海恒瑞医药有限公司 | 苯并二氧六环类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2979511A (en) * | 1959-03-25 | 1961-04-11 | Olin Mathieson | Certain 1, 4-benzodioxanyl imidazolines and corresponding pyrimidines and process |
| PH16249A (en) * | 1980-02-04 | 1983-08-16 | Reckitt & Colmann Prod Ltd | Imidazoline derivatives,its pharmaceutical composition and method of use |
-
1982
- 1982-01-12 NZ NZ199469A patent/NZ199469A/en unknown
- 1982-01-13 CA CA000394056A patent/CA1176638A/en not_active Expired
- 1982-01-18 US US06/340,461 patent/US4397860A/en not_active Expired - Fee Related
- 1982-01-22 GB GB8201828A patent/GB2092139B/en not_active Expired
- 1982-01-25 DE DE8282300365T patent/DE3262919D1/de not_active Expired
- 1982-01-25 EP EP82300365A patent/EP0058006B1/en not_active Expired
- 1982-01-26 AR AR288247A patent/AR229957A1/es active
- 1982-01-26 PH PH26794A patent/PH17747A/en unknown
- 1982-01-27 FI FI820262A patent/FI67544C/fi not_active IP Right Cessation
- 1982-01-28 AU AU79926/82A patent/AU545344B2/en not_active Ceased
- 1982-01-28 GR GR67143A patent/GR75168B/el unknown
- 1982-01-28 SU SU823385605A patent/SU1197566A3/ru active
- 1982-01-28 IL IL64880A patent/IL64880A/xx unknown
- 1982-01-28 ES ES509131A patent/ES8302694A1/es not_active Expired
- 1982-01-28 NO NO820258A patent/NO156865C/no unknown
- 1982-01-29 ZW ZW18/82A patent/ZW1882A1/xx unknown
- 1982-01-29 PT PT74354A patent/PT74354B/pt unknown
- 1982-01-29 CS CS82631A patent/CS245766B2/cs unknown
- 1982-01-29 DK DK40482A patent/DK40482A/da not_active Application Discontinuation
- 1982-01-29 HU HU82273A patent/HU190983B/hu not_active IP Right Cessation
- 1982-01-29 IE IE209/82A patent/IE52310B1/en unknown
- 1982-02-19 PL PL1982235152A patent/PL137716B1/pl unknown
Non-Patent Citations (1)
| Title |
|---|
| Эльдерфильд Р. Гетероциклические соединени , т. 5.-М., 196 с. 224. * |
Also Published As
| Publication number | Publication date |
|---|---|
| DK40482A (da) | 1982-07-31 |
| US4397860A (en) | 1983-08-09 |
| CA1176638A (en) | 1984-10-23 |
| IE820209L (en) | 1982-07-30 |
| IL64880A (en) | 1985-04-30 |
| AU545344B2 (en) | 1985-07-11 |
| FI67544B (fi) | 1984-12-31 |
| IE52310B1 (en) | 1987-09-02 |
| GB2092139A (en) | 1982-08-11 |
| ES509131A0 (es) | 1983-01-16 |
| EP0058006A1 (en) | 1982-08-18 |
| AR229957A1 (es) | 1984-01-31 |
| PT74354B (en) | 1983-07-04 |
| PH17747A (en) | 1984-11-27 |
| PL137716B1 (en) | 1986-07-31 |
| DE3262919D1 (en) | 1985-05-15 |
| FI67544C (fi) | 1985-04-10 |
| FI820262L (fi) | 1982-07-31 |
| PL235152A1 (en) | 1983-07-18 |
| AU7992682A (en) | 1982-08-05 |
| GR75168B (enExample) | 1984-07-13 |
| NO156865B (no) | 1987-08-31 |
| NZ199469A (en) | 1984-03-16 |
| HU190983B (en) | 1986-12-28 |
| GB2092139B (en) | 1984-10-31 |
| ES8302694A1 (es) | 1983-01-16 |
| PT74354A (en) | 1982-02-01 |
| IL64880A0 (en) | 1982-03-31 |
| NO156865C (no) | 1987-12-09 |
| EP0058006B1 (en) | 1985-04-10 |
| NO820258L (no) | 1982-08-02 |
| CS245766B2 (en) | 1986-10-16 |
| ZW1882A1 (en) | 1982-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69303569T2 (de) | Arylalkyl(thio)amide mit Melatonin-Rezeptor-Selektivität und Prozess zu ihrer Darstellung | |
| US4599347A (en) | Tetrahydro-naphth (2.3-d) imidazole derivatives | |
| SU1197566A3 (ru) | Способ получени производных имидазолина | |
| EP0125783B1 (en) | Dopamine-beta-hydroxylase inhibitors | |
| DE3631824A1 (de) | Cycloalkano(1.2-b)indol-sulfonamide | |
| RU1779251C (ru) | Способ получени 1-(4-аминофенил)-4-метил-7,8-метилендиокси-3,4-дигидро-5Н-2,3-бензодиазепина или его кислотно-аддитивных солей | |
| HU187295B (en) | Process for producing imidazoline derivatives and pharmaceutical pharmaceutical compositions containing them | |
| RU2133741C1 (ru) | Производные n-замещенных гексагидроазепинов и фармацевтическая композиция на их основе | |
| FR2548666A1 (fr) | Nouveaux derives du nor-tropane et du granatane, leur procede de preparation et leur application en therapeutique | |
| JPH0794417B2 (ja) | Ｎ−アミノブチル−ｎ−フェニルアリールアミド誘導体 | |
| Borne et al. | Conformational analogs of antihypertensive agents related to guanethidine | |
| EP0092328B1 (en) | Imidazoline derivatives | |
| DE69021490T2 (de) | Phenoxyheterozyklische Verbindungen. | |
| US3585213A (en) | Benzodioxole derivatives of guanidine | |
| FR2685637A1 (fr) | Compositions therapeutiques a base de nouveaux derives de la benzofuranylimidazole. | |
| LV11462B (en) | Enantiomers of 4- (5- fluoro- 2,3- dihydro- 1h- inden- 2- yl)- 1h- imidazole | |
| NO137893B (no) | Analogifremgangsm}te for fremstilling av terapeutisk aktive 1-m-trifluormetylfenyl-2-cyanoalkylaminopropaner | |
| JPS6043068B2 (ja) | アゼピノ〔１，２，３−１ｍ〕−β−カルボリン誘導体及びその製法 | |
| NO137498B (no) | Mellomprodukt for fremstilling av lokalanestetisk virksomt 2-(n-n-propyl-tert.-amylamino)-2`, 6`-acetoxylidid | |
| EP0433036A2 (en) | Polycyclic nitrile compounds and pharmaceutical compositions thereof | |
| JPH0720934B2 (ja) | 新規１，４―ジヒドロピリジン誘導体 | |
| DE2720968A1 (de) | Neue 1-acyl-2-hydroxy-1,3-diaminopropane, verfahren zu deren herstellung und arzneimittel | |
| CS217947B1 (cs) | 2-Benzylcyklopentylamin, jeho methylderiváty a soli | |
| WO1983004022A1 (fr) | Nouvelles phenyloxoalcoyle piperidines, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant | |
| CS263982B1 (cs) | 4-(aminoalkoxy)dibenzo(b,e)thiepin-ll(6H)-ony a jejich hydrochloridy |